Kroese Mark, Zimmern Ron L, Pinder Sarah E
Consultant in Public Health Medicine, Strangeways Research Laboratory, Worts Causeway, Cambridge CB1 8RN, UK.
J R Soc Med. 2007 Jul;100(7):326-9. doi: 10.1177/014107680710000715.
The development of new drugs and associated pharmacogenetic tests will provide an increasing number of challenges to health care systems. In particular, how to evaluate their benefits, prioritize for commissioning purposes and implement a service to provide them in a timely manner. This paper presents an overview of HER2 testing for trastuzumab (Herceptin) treatment in breast cancer cases. Immunohistochemistry and fluorescence in situ hybridization laboratory techniques are described and their HER2 testing performances are compared. Future options for the national provision of HER2 testing by the National Health Service in the UK are also discussed.
新型药物及相关药物遗传学检测的发展将给医疗保健系统带来越来越多的挑战。特别是，如何评估它们的益处、为委托目的确定优先次序以及实施一项服务以便及时提供这些药物。本文概述了乳腺癌病例中曲妥珠单抗（赫赛汀）治疗的HER2检测。描述了免疫组织化学和荧光原位杂交实验室技术，并比较了它们的HER2检测性能。还讨论了英国国家医疗服务体系在全国范围内提供HER2检测的未来选择。
